An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed 2 or More Tyrosine Kinase Inhibitor Therapies

Trial Profile

An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed 2 or More Tyrosine Kinase Inhibitor Therapies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Omacetaxine mepesuccinate (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms SYNSINCT
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2016 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020, according to ClinicalTrials.gov record.
    • 01 Mar 2016 Planned primary completion date changed from 1 Sep 2019 to 1 May 2020, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top